JAC Advance Access originally published online on December 12, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 5-8
© 2003 The British Society for Antimicrobial Chemotherapy
Leading Article |
Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide
Laboratory of Molecular Immunology of Infection and Inflammation, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille cedex, France
Keywords: immunotherapy, murabutide, HIV-1
| The first 150 words of the full text of this article appear below. |
 |
The need for immunotherapy in the management of HIV disease |
|---|
Although highly active antiretroviral therapy (HAART) can provide sustained control of human immunodeficiency virus 1 (HIV-1) replication, it allows for only a partial immune reconstitution. Moreover, the use of HAART is clearly limited by the lack of elimination of virus reservoirs, the adverse effects of therapy and the potential for development of viral resistance. Following HAART, the number of both memory and naive T cells in the periphery may increase, but a significant immune reconstitution is not observed in all treated patients.1 In addition, immunological measures generally do not normalize to levels seen in persons without HIV infection, and virus-specific T-cell responses frequently remain impaired.1,2 Approaches aimed at correcting the immune deficiencies of HIV-1 infection, and stimulating virus-specific responses, have mostly targeted the restoration of defective elements of adaptive immunity, and have been the subject of several recent reviews.3–5 These approaches include the use of cytokines and growth factors, virus-specific
|
Experimental evidence supporting the use of murabutide for the immunotherapy of HIV-1 infection |
|---|
|
Clinical development of murabutide in HIV-1 disease |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Zarrilli, M.-F. Tripodi, A. Di Popolo, R. Fortunato, M. Bagattini, M. Crispino, A. Florio, M. Triassi, and R. Utili Molecular epidemiology of high-level aminoglycoside-resistant enterococci isolated from patients in a university hospital in southern Italy J. Antimicrob. Chemother., November 1, 2005; 56(5): 827 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Stampone, M. Del Grosso, D. Boccia, and A. Pantosti Clonal Spread of a Vancomycin-Resistant Enterococcus faecium Strain among Bloodstream-Infecting Isolates in Italy J. Clin. Microbiol., April 1, 2005; 43(4): 1575 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Marchetti, F. Franzetti, and A. Gori Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap? J. Antimicrob. Chemother., April 1, 2005; 55(4): 401 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sofianou, S. Pournaras, M. Giosi, A. Polyzou, A. N. Maniatis, and A. Tsakris Substantially increased faecal carriage of vancomycin-resistant enterococci in a tertiary Greek hospital after a 4 year time interval J. Antimicrob. Chemother., July 1, 2004; 54(1): 251 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cocude, M.-J. Truong, O. Billaut-Mulot, V. Delsart, E. Darcissac, A. Capron, Y. Mouton, and G. M. Bahr A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication J. Gen. Virol., December 1, 2003; 84(12): 3215 - 3225. [Abstract] [Full Text] [PDF]
|
|